Does Peptara sell IGF-1 LR3, MGF, or Follistatin?

No. Peptara does NOT stock IGF-1 LR3, MGF, or Follistatin-344. These are the three peptides most often discussed for direct hypertrophy in biohacker literature. We choose not to carry them because the human safety data is thin, no regulatory pathway exists for hypertrophy claims, and the gray-market counterfeit rate for these specific compounds is high. Our muscle-growth-relevant SKUs are listed above: CJC-1295/Ipamorelin and Tesamorelin (GH-axis), BPC-157, TB-500, KLOW Combo (training-volume), MOTS-c and SLU-PP-332 (energy / training capacity).

Are CJC-1295/Ipamorelin and Tesamorelin the same thing?

No. CJC-1295 is a GHRH analog and Ipamorelin is a GHRP mimetic; stacked together they synergize, with the GHRH amplifying GH pulse amplitude and the GHRP triggering the pulse. Tesamorelin is a GHRH analog alone (no GHRP). Tesamorelin has FDA approval (Egrifta, 2010, for HIV-associated lipodystrophy) and is dosed daily. CJC/Ipa is a research compound combo and is typically dosed nightly 5 days per week. Both elevate IGF-1; Tesamorelin produces more sustained GH exposure, CJC/Ipa produces more pulsatile (more physiologic) GH release.

Can I run BPC-157 or TB-500 for muscle growth specifically?

BPC-157 and TB-500 do not directly drive hypertrophy. They drive recovery. The mechanism for hypertrophy here is indirect: faster recovery between training sessions allows more frequent and heavier mechanical loading, and mechanical loading is the proximate driver of muscle protein synthesis. If you cannot train hard because of tendinopathy, joint pain, or chronic soft-tissue injuries, these peptides remove the bottleneck and your hypertrophy programming becomes the limiter again. This is also why they appear on the recovery hub and the muscle-growth hub: same compound, different mechanism framing for different goals.

What is the best muscle-growth stack from the Peptara catalog?

For a hard-training lifter with intact joints: CJC-1295/Ipamorelin (GH-axis pulse during sleep) plus BPC-157 (tendon and joint resilience). For a lifter returning from injury or with multiple recovery sites: KLOW Combo (systemic recovery) plus CJC-1295/Ipamorelin (GH-axis support). For someone prioritizing body recomposition over pure mass: Tesamorelin (sustained GH/IGF-1) plus MOTS-c (insulin sensitivity and metabolic flexibility). All three stacks should be paired with a structured progressive-overload program, protein intake at 1.6 to 2.2g per kg body weight, and 7-plus hours of sleep nightly. The peptides are training-amplifiers, not training-replacements.

Are these peptides FDA-approved for muscle growth?

No. None of the seven peptides on this page is FDA-approved for muscle growth or hypertrophy as an indication. Tesamorelin is FDA-approved for HIV-associated lipodystrophy (a fat-distribution condition, not a hypertrophy indication). All other peptides on this page are research compounds. We are not making hypertrophy claims; we are describing mechanisms studied in research settings and disclosed dosing protocols used in biohacker communities. Talk to your physician before running any GH-axis peptide protocol, especially if you have a history of cancer, diabetes, or pituitary dysfunction.

Can I stack GH-axis peptides with anabolic steroids?

Many lifters do. GH-axis peptides (CJC/Ipa, Tesamorelin) work via the endogenous growth hormone and IGF-1 pathway, which is mechanistically separate from the androgen receptor pathway that anabolic steroids activate. The two stacks can theoretically combine. However, both classes carry independent risk profiles: GH/IGF-1 elevation is associated with edema, carpal-tunnel symptoms, and theoretical malignancy risk; androgen use carries cardiovascular, lipid, hepatic, and HPTA-suppression concerns. We are not advising or facilitating steroid use. We are answering a question that comes up. Get blood work before, during, and after any combined protocol.

How long does it take to see muscle-growth results from peptides?

Honest answer: peptides do not add mass on top of bad training. Even the most direct GH-axis stack will produce subtle results without progressive overload. With training dialed in, expect: 1 to 2 weeks for sleep-depth improvements on CJC/Ipa; 4 to 8 weeks for early recovery and training-capacity gains; 12 to 24 weeks for visible body-composition changes on a well-run stack. Tesamorelin is slower-onset (12 to 26 weeks). BPC-157 and TB-500 effects on training capacity often appear inside the first 2 to 4 weeks but the hypertrophy that follows is downstream of the resumed training. Individual response varies substantially.

Topic hub: muscle growth

Best Peptides for Muscle Growth: Ranked by Anabolic Mechanism

Q: Which peptide is best for direct muscle growth?

No peptide in the Peptara catalog directly drives hypertrophy the way IGF-1 LR3, MGF (Mechano Growth Factor), or Follistatin-344 do in research literature. Peptara does NOT stock those three. The closest mechanism in our catalog is CJC-1295/Ipamorelin: it pulses endogenous growth hormone, which raises IGF-1, which drives muscle protein synthesis via the PI3K/Akt/mTOR pathway. Tesamorelin works the same axis (GHRH analog) without the GHRP component. The remaining peptides (BPC-157, TB-500, KLOW, MOTS-c, SLU-PP-332) support hypertrophy indirectly by enabling more training volume or improving training capacity.

Seven compounds ranked by mechanism proximity to hypertrophy. From direct GH/IGF-1 axis (CJC-1295/Ipamorelin, Tesamorelin) to training-volume enablers (BPC-157, TB-500) to energy and exercise-mimetic compounds (MOTS-c, SLU-PP-332). All research compounds. Peptara does not stock direct hypertrophy peptides (IGF-1 LR3, MGF, Follistatin-344); we explain why below.

Verdict in 7 lines

CJC-1295/Ipamorelin: GHRH + GHRP combo pulses endogenous GH and IGF-1. Closest mechanism to direct hypertrophy in the catalog.
Tesamorelin: GHRH analog alone. Sustained IGF-1 elevation. FDA-approved (Egrifta, 2010) for HIV-associated lipodystrophy.
BPC-157: tendon and gut repair removes recovery bottlenecks, enabling more frequent and heavier mechanical loading.
TB-500: muscle and soft-tissue repair, longer half-life systemic recovery.
KLOW Combo: 4-peptide blend (BPC + TB-500 + GHK-Cu + KPV) for multi-site recovery in one vial.
MOTS-c: mitochondrial AMPK activator. Insulin sensitivity and training-capacity support.
SLU-PP-332: ERR agonist exercise mimetic. Preclinical mouse data; not validated for hypertrophy in humans.

Ranked by anabolic mechanism

Ordering reflects mechanism proximity to hypertrophy, not trial effect size. No head-to-head human hypertrophy trials exist across these compounds.

Order	Peptide	Mechanism	Pathway to Hypertrophy	Evidence	Peptara Cost
1	CJC-1295/Ipamorelin	GHRH analog + GHRP mimetic combo	Pulses endogenous GH, downstream IGF-1, MPS via PI3K/Akt/mTOR	Endocrinology literature; widely used research compound for GH/IGF-1 elevation	$84 to $169 first-time
2	Tesamorelin	GHRH analog (no GHRP)	Sustained GH pulse, IGF-1 elevation, MPS support	FDA-approved 2010 (Egrifta, HIV lipodystrophy). Off-label / research for body composition.	about $440/mo first-time
3	BPC-157	Pro-angiogenic, growth-factor upregulation	Tendon/ligament/gut repair, enables increased training frequency and load tolerance	Extensive preclinical (Sikiric et al, 1990s to 2020s)	$89 to $177 first-time
4	TB-500	Actin-sequestering thymosin beta-4 fragment	Muscle and soft-tissue repair, systemic angiogenesis, longer half-life recovery	Preclinical plus equine clinical use plus human anecdote	$162 to $324 first-time
5	KLOW Combo	4-peptide systemic recovery blend (BPC + TB-500 + GHK-Cu + KPV)	Multi-site repair, single-vial convenience for systemic recovery between training blocks	Peptara stack formulation; literature on each individual peptide	$68 to $136 first-time
6	MOTS-c	Mitochondrial-encoded peptide, AMPK activator	Mitochondrial biogenesis, insulin sensitivity, supports training capacity and protein-synthesis fueling	Lee et al, Cell Metab 2015; preclinical plus small human studies	$85 to $170 first-time
7	SLU-PP-332	ERR agonist exercise mimetic	Endurance and oxidative adaptation; hypertrophy data not primary endpoint	Billon et al, J Pharmacol Exp Ther 2023 (mouse only)	$157/vial, biohacker dosing varies

Read this before quoting the ranking

Ordering reflects mechanism proximity to hypertrophy, not effect size. No head-to-head human hypertrophy trials exist across these compounds. The GH-axis tier is mechanistically closest to direct hypertrophy via IGF-1. The training-volume tier supports hypertrophy by enabling more frequent and heavier mechanical loading. The energy tier supports training capacity. All seven are research compounds. None are FDA-approved for hypertrophy.

Decide by training goal

Six goal profiles, six recommendations.

Goal A

Sleep-driven recovery + lean-mass retention

CJC-1295 (GHRH analog) plus Ipamorelin (GHRP mimetic) combo pulses endogenous GH during sleep, raising IGF-1 and supporting muscle protein synthesis. Nightly dosing aligns with the body's natural overnight GH window.

Pick: CJC-1295/Ipamorelin

No dedicated product page. WhatsApp for ordering.

Goal B

Sustained GH/IGF-1 + body recomposition

Tesamorelin is a GHRH analog alone (no GHRP). FDA-approved 2010 for HIV-associated lipodystrophy. Produces more sustained GH exposure than the CJC/Ipa pulse pattern. Daily dosing.

Pick: Tesamorelin

No dedicated product page. WhatsApp for ordering.

Goal C

Tendon and joint resilience for hard training

Body Protection Compound (BPC-157). Removes recovery bottlenecks at tendon, ligament, and joint sites so hypertrophy programming becomes the limiter again instead of soft-tissue injury.

Pick: BPC-157

BPC-157 product →

Goal D

Multi-site recovery / returning from injury

KLOW Combo is a Peptara four-peptide blend (BPC-157 + TB-500 + GHK-Cu + KPV) in one vial. Convenience play for lifters with multiple recovery sites or returning from a layoff.

Pick: KLOW Combo

No dedicated product page. WhatsApp for ordering.

Goal E

Insulin sensitivity + training capacity

MOTS-c is a mitochondrial-encoded peptide that activates AMPK and drives mitochondrial biogenesis. Improves insulin sensitivity and supports training-capacity gains over weeks of dosing.

Pick: MOTS-c

No dedicated product page. WhatsApp for ordering.

Goal F

GH-axis + training-volume elite stack

CJC-1295/Ipamorelin (overnight GH pulse) plus BPC-157 (joint and tendon resilience). Most common muscle-growth stack for intermediate-to-advanced lifters running 4-plus sessions per week.

Pick: CJC-1295/Ipa + BPC-157

BPC-157 product →

Mechanism tiers

Three tiers, seven compounds, ordered by mechanism distance to hypertrophy.

Tier 1: GH-axis

CJC-1295/Ipa + Tesamorelin

Closest mechanism to direct hypertrophy. Both compounds pulse endogenous growth hormone, which raises IGF-1, which drives muscle protein synthesis via the PI3K/Akt/mTOR pathway. CJC/Ipa uses a GHRH analog plus GHRP mimetic combo for pulsatile pulses; Tesamorelin is GHRH alone for sustained exposure.

Tier 2: Training-volume enablers

BPC-157 + TB-500 + KLOW

Indirect hypertrophy via recovery to mechanical loading to muscle protein synthesis. BPC-157 owns tendon and gut repair; TB-500 is a thymosin beta-4 fragment with broader systemic recovery and longer half-life; KLOW bundles BPC + TB-500 + GHK-Cu + KPV in one vial for multi-site repair.

Tier 3: Energy + exercise mimetic

MOTS-c + SLU-PP-332

Supports training capacity, not hypertrophy directly. MOTS-c activates AMPK and drives mitochondrial biogenesis. SLU-PP-332 is an ERR agonist with preclinical mouse data only. Best used as adjuncts, not primary mass-building agents.

Cost breakdown

Peptara monthly cost ranges in USD with first-time discount applied. Cost formula: vial price times 4.33 weeks per month, divided by weeks per vial.

Peptide	Vial	First-time / Retail	Common Dose	Monthly first-time	Monthly retail
CJC-1295/Ipa	10mg	$130 / $153	300 to 600mcg SC at bedtime, 5d/wk	$84 to $169	$99 to $199
Tesamorelin	10mg	$145 / $170	1mg/day SC	about $440	about $515
BPC-157	20mg	$117 / $138	250 to 500mcg, 1 to 2x daily	$89 to $177	$105 to $209
TB-500	10mg	$187 / $220	2mg 2x/wk loading x 4wk, then 2mg/wk	$162 to $324	$190 to $381
KLOW Combo	80mg	$179 / $210	1 to 2mg blend SC daily	$68 to $136	$80 to $160
MOTS-c	40mg	$157 / $185	5 to 10mg/wk	$85 to $170	$100 to $200
SLU-PP-332	5mg	$157 / $185	Research-only, varies	Varies	Varies

Monthly cost calculation: vial price times 4.33 weeks/month divided by weeks per vial. Doses always in units, never mL. See the reconstitution guide for full math.

Stacking framework

Common stacks, specialty stacks, and sequencing rules.

Workhorse stacks

CJC-1295/Ipa + BPC-157 (GH-axis pulse + tendon resilience)
KLOW Combo + CJC-1295/Ipa (systemic recovery + GH pulse)
Tesamorelin + MOTS-c (sustained GH/IGF-1 + metabolic flexibility for recomposition)

Specialty stacks

TB-500 + CJC-1295/Ipa (muscle repair + GH pulse for high-volume blocks)
KLOW Combo solo (single-vial multi-site recovery)
Tesamorelin + BPC-157 (sustained GH + joint resilience for older lifters)

Sequencing

Start GH-axis 4 to 8 weeks before peak training block
Layer BPC/TB during high-volume phases
Cycle GH-axis 12 to 16 weeks on, 4 to 8 weeks off
Never stack two GHRH analogs (CJC + Tesamorelin redundant)
KLOW already contains BPC + TB-500; do NOT stack KLOW with separate BPC or TB-500

Why Peptara does not stock IGF-1 LR3, MGF, or Follistatin-344

Three peptides come up in every muscle-growth conversation: IGF-1 LR3 (Long R3 variant of insulin-like growth factor 1), MGF (Mechano Growth Factor, a splice variant of IGF-1 thought to drive satellite-cell activation post-mechanical damage), and Follistatin-344 (a myostatin inhibitor that theoretically removes the brake on muscle growth).

Peptara does not stock these. Three reasons.

Thin human safety data. IGF-1 LR3 elevates IGF-1 supraphysiologically and the long-term safety profile of sustained IGF-1 elevation is not well-characterized in healthy adults.
No FDA-approved indication for hypertrophy use. Means there is no regulatory pathway and no manufacturing oversight for finished pharmaceutical product in this category.
High gray-market counterfeiting rate. For these three specific compounds relative to GLP-1s or BPC-157. We do not want to risk our COA program on compounds where the source pool is contaminated.

Our muscle-growth-relevant catalog (the seven SKUs ranked above) is the honest answer to "what does Peptara sell for muscle growth." It is not the maximalist answer.

Side effects by mechanism group

Three profiles to know. Notes below are not exhaustive.

GH-axis (CJC/Ipa, Tesamorelin)

Water retention, mild numbness or tingling in extremities (first 2 to 3 weeks), occasional vivid dreams. IGF-1 elevation with longer protocols, monitor labs over 3 months. Avoid in active malignancy and active diabetic retinopathy. Hypoglycemia risk if stacked with insulin or sulfonylureas.

Training-volume (BPC + TB + KLOW)

Generally well-tolerated. Injection-site reactions most common. Theoretical pro-angiogenic concerns in active or recent cancer (require physician oversight). KLOW includes KPV (anti-inflammatory tripeptide), and inherits each component's caveats.

Energy (MOTS-c, SLU-PP-332)

Limited human data overall. MOTS-c well-tolerated in small studies. SLU-PP-332 long-term human safety not established (preclinical mouse data only). Standard research-compound caveats apply.

Timeline expectations

How long until you see training-side or body-composition effects.

Peptide	Dose Schedule	Time to Visible Effect
CJC-1295/Ipa	Nightly SC, 5d/wk	1 to 2 weeks for sleep depth; 4 to 12 weeks for measurable lean-mass / body-composition changes
Tesamorelin	Daily SC	4 to 12 weeks for IGF-1 elevation; 12 to 26 weeks for measurable body-composition shifts
BPC-157	Daily SC (1 to 2x)	1 to 3 weeks for early recovery improvement; 4 to 8 weeks for sustained training-volume increase
TB-500	Loading 2x/wk x 4wk, then weekly	2 to 4 weeks for early effect; 6 to 12 weeks for full systemic recovery support
KLOW Combo	Daily SC	2 to 6 weeks for systemic recovery; longer than single compounds because per-peptide doses are lower
MOTS-c	2x weekly SC	4 to 12 weeks for insulin sensitivity and metabolic markers
SLU-PP-332	Research-protocol-dependent	No human hypertrophy timeline established

Frequently asked questions

Next steps

BPC-157 product page

Body Protection Compound. 20mg/vial. $117 first-time / $138 retail. The only muscle-growth-tier-3 peptide with a dedicated product page on Peptara.

View product

Peptide glossary

120 terms across pharmacology, dosing, reconstitution, safety, regulatory, and mechanism. Anchors used on this page: IGF-1, GHRH, thymosin beta-4, AMPK, mitochondrial biogenesis, KPV, research compound.

Open glossary

Reconstitution guide

4-step method plus units-not-mL calculator. Required reading before any research-vial protocol.

Open guide

Full /vs/* cluster

BPC vs TB-500 Reta vs Tirz Reta vs Ozempic Tirz vs Ozempic

Different goal? Switch hubs

Muscle-growth completes the body-composition trifecta. The other two hubs are:

Peptides for Fat Loss (ranked guide) →Peptides for Recovery (ranked guide) →

FAQ →About Peptara →Find your protocol quiz →

Not sure which muscle-growth peptide fits

Not sure which muscle-growth peptide fits your training cycle or stack? Message the Peptara team on WhatsApp.

For CJC-1295/Ipamorelin, Tesamorelin, TB-500, KLOW Combo, MOTS-c, and SLU-PP-332 (no dedicated product page yet), WhatsApp is the order channel and includes protocol setup.

Chat on WhatsApp Browse all 15 peptides →